-
Je něco špatně v tomto záznamu ?
High familial risks in some rare cancers may pinpoint to hidden germline genetics: focus on esophageal, stomach, small intestinal, testis, thyroid and bone cancers
K. Hemminki, O. Hemminki, A. Koskinen, A. Hemminki, A. Försti
Status neindexováno Jazyk angličtina Země Polsko
Typ dokumentu časopisecké články, přehledy
NLK
BioMedCentral
od 2003-12-01
BioMedCentral Open Access
od 2003
Directory of Open Access Journals
od 2003
Free Medical Journals
od 2003
PubMed Central
od 2003
Europe PubMed Central
od 2003
ProQuest Central
od 2003-01-01
Open Access Digital Library
od 2003-01-01
Open Access Digital Library
od 2003-01-01
Health & Medicine (ProQuest)
od 2003-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2003
Springer Nature OA/Free Journals
od 2003-12-01
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
BACKGROUND: Germline genetic susceptibilities of rare cancers of the esophagus, stomach, small intestine, testis, (nonmedullary) thyroid gland and bone with high familial risks are not well known. Here, we use familial risk data from the Swedish Family-Cancer Database which contains records of cancers in Swedish families obtained over a century. We compare familial risks for offspring diagnosed with any of these cancers when their parent had or had not that cancer. We review the global literature of the reported constitutional variants that may explain part of the familial risk. MAIN BODY: Familial risks for esophageal and stomach cancers are about 2.0 and apart from early-onset stomach cancer few high-risk variants are known. Genetic studies may be hampered by dominant environmental risk factors for these cancers. Small intestinal carcinoids have a very high familial risk (28 between siblings) but no high-risk genes have been identified to explain this. Low-risk polygenic variants have been identified. Small intestinal adenocarcinoma is a manifestation in Lynch syndrome. Testicular and thyroid cancers are characterized by high familial risk (about 5) which may be explained largely by a polygenic background, although thyroid cancer is a component in a number of rare cancer syndromes. Several predisposing genes have been identified for bone cancer (familial risk 7). CONCLUSIONS: The discussed cancers are rare and they present with a relatively high familial risk, in spite of lacking identified high-penetrant constitutional variants. It is possible that the polygenic component, already recognized for testis cancer, is stronger than previously expected. Thus polygenic models with rare high/moderate- and low-risk variants could fit the familial risk and shape the germline genetic landscape of these cancers. Polygenic background may have clinical implications.
Biomedical Center Faculty of Medicine Charles University Pilsen 30605 Czech Republic
Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland
Department of Urology Helsinki University Hospital Helsinki Finland
Division of Pediatric Neurooncology German Cancer Research Center Heidelberg Germany
Hopp Children's Cancer Center Heidelberg Germany
Skin and Allergy Hospital Helsinki University Hospital and University of Helsinki Helsinki Finland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25008347
- 003
- CZ-PrNML
- 005
- 20250422095647.0
- 007
- ta
- 008
- 250408s2025 pl f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13053-024-00303-6 $2 doi
- 035 __
- $a (PubMed)40016794
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a pl
- 100 1_
- $a Hemminki, Kari $u Biomedical Center, Faculty of Medicine, Charles University, Pilsen, 30605, Czech Republic. k.hemminki@dkfz.de $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany. k.hemminki@dkfz.de
- 245 10
- $a High familial risks in some rare cancers may pinpoint to hidden germline genetics: focus on esophageal, stomach, small intestinal, testis, thyroid and bone cancers / $c K. Hemminki, O. Hemminki, A. Koskinen, A. Hemminki, A. Försti
- 520 9_
- $a BACKGROUND: Germline genetic susceptibilities of rare cancers of the esophagus, stomach, small intestine, testis, (nonmedullary) thyroid gland and bone with high familial risks are not well known. Here, we use familial risk data from the Swedish Family-Cancer Database which contains records of cancers in Swedish families obtained over a century. We compare familial risks for offspring diagnosed with any of these cancers when their parent had or had not that cancer. We review the global literature of the reported constitutional variants that may explain part of the familial risk. MAIN BODY: Familial risks for esophageal and stomach cancers are about 2.0 and apart from early-onset stomach cancer few high-risk variants are known. Genetic studies may be hampered by dominant environmental risk factors for these cancers. Small intestinal carcinoids have a very high familial risk (28 between siblings) but no high-risk genes have been identified to explain this. Low-risk polygenic variants have been identified. Small intestinal adenocarcinoma is a manifestation in Lynch syndrome. Testicular and thyroid cancers are characterized by high familial risk (about 5) which may be explained largely by a polygenic background, although thyroid cancer is a component in a number of rare cancer syndromes. Several predisposing genes have been identified for bone cancer (familial risk 7). CONCLUSIONS: The discussed cancers are rare and they present with a relatively high familial risk, in spite of lacking identified high-penetrant constitutional variants. It is possible that the polygenic component, already recognized for testis cancer, is stronger than previously expected. Thus polygenic models with rare high/moderate- and low-risk variants could fit the familial risk and shape the germline genetic landscape of these cancers. Polygenic background may have clinical implications.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Hemminki, Otto $u Department of Urology, Helsinki University Hospital, Helsinki, Finland $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
- 700 1_
- $a Koskinen, Anni $u Department of Otorhinolaryngology- Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland $u Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
- 700 1_
- $a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
- 773 0_
- $w MED00175714 $t Hereditary cancer in clinical practice $x 1731-2302 $g Roč. 23, č. 1 (2025), s. 9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40016794 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250408 $b ABA008
- 991 __
- $a 20250422095649 $b ABA008
- 999 __
- $a ok $b bmc $g 2306347 $s 1245422
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2025 $b 23 $c 1 $d 9 $e 20250227 $i 1731-2302 $m Hereditary cancer in clinical practice $n Hered Cancer Clin Pract $x MED00175714
- LZP __
- $a Pubmed-20250408